SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$88.98
+1.98%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.80
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.36
- EPS estimate
- -$0.76
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +9.3%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $123
- PT range
- $115 – $130
- Analysts
- 7
6 Buy1 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026